President and CEO Katherine Stueland stated that GeneDx achieved significant milestones in 2024, including surpassing $95 million in Q4 revenue and expanding gross margins to 70%. She highlighted the ...
The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their blood having a better survival rate, finds a new study that uses a pioneering ...
GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2024.
The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their ...
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by the progressive degeneration of motor neurons, ...